**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 69435

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Increased levels of lactate dehydrogenase and hypertension are associated with severe illness of COVID-19**

Jin ZM *et al*. Hypertension and COVID-19

Zhen-Mu Jin, Ji-Chan Shi, Mo Zheng, Que-Lu Chen, Yue-Ying Zhou, Fang Cheng, Jing Cai, Xian-Gao Jiang

**Zhen-Mu Jin, Mo Zheng,** Department of Rheumatology, Immunology and Allergy, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai University, Affiliated Dingli Clinical Institute of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China

**Ji-Chan Shi, Yue-Ying Zhou, Fang Cheng, Jing Cai, Xian-Gao Jiang,** Department of Infectious Diseases, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai University, Affiliated Dingli Clinical Institute of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China

**Que-Lu Chen,** Department of Radiology, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai University, Affiliated Dingli Clinical Institute of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China

**Author contributions:** Jiang XG and Jin ZM designed the study; Jin ZM, Shi JC, Zheng M, and Chen QL performed the study and collected the data; Zhou YY, Chen F, and Cai J analyzed the data; Jin ZM drafted the manuscript; and all authors have read and approved the final manuscript.

**Supported by** the Wenzhou Major Technology Innovation Project, No. ZY202004.

**Corresponding author: Xian-Gao Jiang, MD, Professor,** Department of Infectious Diseases, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai University, Affiliated Dingli Clinical Institute of Wenzhou Medical University, No. 252 Bailidong Road, Wenzhou 325000, Zhejiang Province, China. xiangao368@163.com

**Received:** June 30, 2021

**Revised:** July 26, 2021

**Accepted:** November 25, 2021

**Published online:** January 7, 2022

**Abstract**

BACKGROUND

Coronavirus disease 2019 (COVID-19) is amid an ongoing pandemic. It has been shown that patients with cardiovascular comorbidities are at higher risk of severe illness of COVID-19.

AIM

To find out the relationship between cardiovascular comorbidities and severe illness of COVID-19.

METHODS

The clinical data of 140 COVID-19 patients treated from January 22, 2020 to March 3, 2020 at our hospital were retrospectively collected. The clinical characteristics were compared between patients with mild illness and those with severe illness.

RESULTS

There were 75 male patients and 65 female patients (53.6% *vs* 46.4%). The mean age was 45.4 ± 14.6 years (range, 2-85 years). Most of the patients had mild illness (*n* = 114, 81.4%) and 26 patients had severe illness (18.6%). The most common symptom was fever (*n* = 110, 78.6%), followed by cough (*n* = 82, 58.6%) and expectoration (*n* = 51, 36.4%). Eight patients were asymptomatic but were positive for severe acute respiratory syndrome coronavirus 2 RNA. Patients with severe illness were significantly more likely to be hypertensive than those with mild illness [(10/26, 38.4%) *vs* (22/114, 19.3%), *P* = 0.036]. The levels of lactate dehydrogenase were significantly higher in the severe illness group than in the mild illness group (299.35 ± 68.82 *vs* 202.94 ± 63.87, *P* < 0.001). No patient died in either the severe illness or the mild illness group.

CONCLUSION

Hypertension and elevated levels of lactate dehydrogenase may be associated with severe illness of COVID-19.

**Key Words:** Pneumonia; Virus; COVID-19; Hypertension; Lactate dehydrogenase; Radiology

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Jin ZM, Shi JC, Zheng M, Chen QL, Zhou YY, Cheng F, Cai J, Jiang XG. Increased levels of lactate dehydrogenase and hypertension are associated with severe illness of COVID-19. *World J Clin Cases* 2022; 10(1): 128-135

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i1/128.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i1.128

**Core Tip:** Coronavirus disease 2019 (COVID-19) is amid an ongoing pandemic. It has been shown that patients with cardiovascular comorbidities are at higher risk of severe illness of COVID-19. Although most COVID-19 patients have mild symptoms and generally good outcomes, some of them still show severe illness. Patients with hypertension and elevated levels of lactate dehydrogenase may be at high risk of severe illness of COVID-19.

**INTRODUCTION**

Coronavirus disease 2019 (COVID-19) has rapidly evolved into a pandemic since its first outbreak in Wuhan, China in December 2019. However, there is still no effective drugs for this disease[1,2]. In addition, the symptoms and signs and pathological mechanisms of COVID-19 are very complex, posing great challenges in treating patients. Our hospital is a dedicated hospital for treating patients with COVID-19 in Wenzhou, China, which is 680 km from Wuhan. There is strong economic connectivity and mass migrations between the two cities. The present study aimed to analyze the clinical characteristics of COVID-19 patients from a hospital in Wenzhou, China.

**MATERIALS AND METHODS**

***Patients***

The clinical data of COVID-19 patients treated from January 22, 2020 to March 3, 2020 at our hospital were retrospectively collected. The diagnostic criteria for COVID-19 at our hospital were: (1) Potential exposure to COVID-19; (2) Had fever, respiratory symptoms, radiological abnormalities in the lungs, or leukocytopenia/lymphocytopenia; and (3) Presence of viral RNA in nasopharyngeal specimens. The inclusion criteria were: (1) With laboratory-confirmed COVID-19; (2) With specific outcomes of discharge or death; and (3) Had been examined by chest computed tomography (CT) during hospitalization. Our study was approved by the ethics committee of our hospital.

***Data collection***

All data were retrospectively collected from electronic records of the patients, including sex, age, symptoms, radiological findings, laboratory test results, treatment methods, and patient outcomes. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was tested using quantitative real-time polymerase chain reaction. Blood samples were collected at 7 am after fasting overnight. Disease severity was classified as mild illness (respiratory symptoms and/or radiological findings of pneumonia) and severe illness (respiratory distress and/or need of mechanical ventilation).

***Statistical analysis***

Continuous data are presented as the mean and standard deviation and were compared using the independent student’s *t*-test. Categorical data are presented as counts or percentages and were compared using the Chi-square test. All statistical analyses were performed using SPSS 24.0 (IBM, United States). A *P* value less than 0.05 was considered statistical significance.

**RESULTS**

***Patient general information***

A total of 140 laboratory-confirmed COVID-19 patients were included in our study (Table 1). There were 75 male patients and 65 female patients (53.6% *vs* 46.4%). The mean age was 45.4 ± 14.6 years (range, 2-85 years). Most of the patients had potential exposure to COVID-19 (*n* = 92, 65.7%).

***Clinical characteristics***

The most common symptom was fever (*n* = 110, 78.6%), followed by cough (*n* = 82, 58.6%), expectoration (*n* = 51, 36.4%), fatigue (*n* = 20, 14.3%), shortness of breath (*n* = 15, 10.7%), diarrhea (*n* = 14, 10%), and headache (*n* = 4.3%) (Table 1). Eight patients (5.6%) were asymptomatic but were positive for SARS-CoV-2 RNA. These patients were family members or neighbors of other symptomatic patients and thus were tested for COVID-19.

The most common comorbidity was hypertension (*n* = 32, 22.9%). Other comorbidities included diabetes (*n* = 6), coronary heart disease (*n* = 3), and malignant tumor (*n* = 4). Most of the patients had mild illness (*n* = 114, 81.4%) and 26 had severe illness (18.6%) (Table 1). Patients with severe illness were significantly more likely to be hypertensive than those with mild illness [(10/26, 38.5%) *vs* (22/114, 19.3%), *P* = 0.036].

The results of laboratory tests are shown in Table 2. The leukocyte count was lower than 3.5 × 109/L in 26 patients (18.6%). The lymphocyte count was lower than 1.1 × 109/L in 54 patients (38.6%). Low levels of hemoglobin were present in 16 patients (11.4%). Thrombocytopenia (< 100 × 109/L) was present in three patients. Elevated serum levels of creatinine > 94 μmol/L were noticed in 18 patients. Elevated serum levels of creatine kinase > 200 U/L were noticed in 12 patients, and > 500 U/L in three patients. Elevated serum levels of lactate dehydrogenase were noticed in 37 patients. The level of lactate dehydrogenase was significantly higher in the severe illness group than in the mild illness group (299.35 ± 68.82 *vs* 202.94 ± 63.87, *P* < 0.001). There were significant differences in lymphocyte count, platelet count, levels of total serum protein, prealbumin, blood uric acid, lactate dehydrogenase, C-reactive protein, erythrocyte sedimentation rate, arterial partial pressure of oxygen, and oxygenation index between patients with mild illness and those with severe illness (Table 2).

***Radiologic characteristics in computed tomography***

Only 3 three patients showed no significant radiologic findings (3/140, 2.1%). The radiologic characteristics are shown in Table 3. There was no significant difference in the frequency of affected lung sites between patients with mild illness and those with severe illness. However, significantly more patients with mild illness had ground-glass opacity than those with severe illness (78.9% *vs* 23.1%, *P* < 0.0001). On the contrary, there were significantly more patients with consolidation (100% *vs* 25.4, *P* < 0.0001) and pleural effusion (30.8% *vs* 2.6%, *P* < 0.0001) in the severe illness group than in the mild illness group.

***Treatment outcomes***

High-flow nasal oxygen therapy was used in 22 patients with mild illness (22/114, 19.3%), while all the 26 patients with severe illness used this treatment. Non-invasive mechanical ventilation was used in 4/26 (15.4%) patients with severe illness, while none of the patients with mild illness used this treatment. No tracheal intubation was required in our patients. All patients were cured and discharged as of March 3, 2020.

**DISCUSSION**

Our study retrospectively analyzed 140 patients with laboratory-confirmed COVID-19 and found that patients with severe illness were more likely to have hypertension than those with mild illness. In addition, the level of lactate dehydrogenase was significantly higher in the severe illness group than in the mild illness group.

Fever (78.6%) and cough (58.6%) were the most common symptoms in our patients. This finding is consistent with previous reports[3,4]. However, these symptoms are not specific and many of the patients had early on-set symptoms of fatigue, diarrhea, and myalgia. In addition, eight patients (5.6%) were asymptomatic but were positive for SARS-CoV-2 RNA. Most recent research showed that the rate of asymptomatic infection in the general population may be as high as 80.9%[5,6]. Due to the criteria for diagnosis and patient admission for COVID-19 at our hospital, asymptomatic patients were not tested for viral RNA and thus were not confirmed with the diagnosis of COVID-19.

The existence of comorbidities can increase the risk of more severe illness and mortality in COVID-19 patients[7,8]. The most common comorbidity in our patients was hypertension (22.9%), and patients with severe illness were significantly more likely to be hypertensive than those with mild illness (38.4% *vs* 19.3%). A previous study with 1099 COVID-19 patients also found that hypertension was associated with severe disease[3]. In addition, we found that the levels of lactate dehydrogenase were significantly elevated in patients with severe illness compared to those with mild illness. Lactate dehydrogenase is a biomarker for myocardial injury[9,10]. All these findings suggest that hypertension and the resulting myocardial injury may lead to a poor prognosis in COVID-19. There have been concerns and debates on the roles of the renin-angiotensin system, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in COVID-19 and poor prognosis[11-15]. However, there is no concrete evidence at present suggesting that these anti-hypertensive drugs should be discontinued in hypertensive COVID-19 patients[16,17].

All our patients were examined by CT and only three showed no significant radiologic findings in the lungs. Most patients had signs of involvement of bilateral lungs, especially the lower lobes. Patients with severe illness of COVID-19 had features of involvement of multiple lobes, irregular patches, and consolidations. Significant radiological progression was seen in 32 patients (22.9%) even after 3 to 7 d. Consistent with previous studies[18,19], our findings suggest that COVID-19 patients with mild or no symptoms may be negative in chest CT examinations. Although CT should not be relied on as a method for screening or diagnosing COVID-19, we recommend repeated chest CT for suspected patients in case of symptoms onset or disease progression.

Our study has limitations. First, most of our patients were only diagnosed with COVID-19 and admitted to the hospital when they showed symptoms. This criterion for diagnosis may underestimate the true population of COVID-19 patients. Second, patients with mild symptoms may not visit the clinics and just stay at home. This may potentially increase the proportion of patients with severe illness in our study. Third, the relationship between hypertension and elevated levels of lactate dehydrogenase in COVID-19 patients was not addressed due to the retrospective nature of our study.

**CONCLUSION**

Our study found that most of the laboratory-confirmed COVID-19 patients in Wenzhou, China had mild illness and generally good outcomes. Hypertension and elevated levels of lactate dehydrogenase may be associated with severe illness of COVID-19. Targeting hypertension-associated myocardial injury may be a potential option in the treatment of COVID-19.

**ARTICLE HIGHLIGHTS**

***Research background***

The coronavirus disease 2019 (COVID-19) pandemic is still evolving.

***Research motivation***

Older people are at increased risk of cardiovascular diseases and COVID-19. The relationship between COVID-19 and cardiovascular diseases is poorly understood.

***Research objectives***

Our study aimed to find out the relationship between COVID-19 and cardiovascular diseases.

***Research methods***

The clinical data of 140 COVID-19 patients were retrospectively analyzed. The clinical characteristics were compared between patients with mild illness and those with severe illness.

***Research results***

Patients with severe illness of COVID-19 were more likely to be hypertensive and had significantly higher levels of lactate dehydrogenase than those with mild illness.

***Research conclusions***

The coexistence of hypertension and higher levels of lactate dehydrogenase in patients with severe illness of COVID-19 suggests a close relationship between COVID-19 and cardiovascular diseases.

***Research perspectives***

The relationship between hypertension and elevated levels of lactate dehydrogenase in COVID-19 patients should be addressed in future investigations.

**REFERENCES**

1 **Md Insiat Islam Rabby**. Current Drugs with Potential for Treatment of COVID-19: A Literature Review. *J Pharm Pharm Sci* 2020; **23**: 58-64 [PMID: 32251618 DOI: 10.18433/jpps31002]

2 **Jean SS**, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. *J Microbiol Immunol Infect* 2020; **53**: 436-443 [PMID: 32307245 DOI: 10.1016/j.jmii.2020.03.034]

3 **Guan WJ**, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; **382**: 1708-1720 [PMID: 32109013 DOI: 10.1056/NEJMoa2002032]

4 **Huang C**, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]

5 **Lai CC**, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, Ko WC, Hsueh PR. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. *J Microbiol Immunol Infect* 2020; **53**: 404-412 [PMID: 32173241 DOI: 10.1016/j.jmii.2020.02.012]

6 **Wang Y**, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. *J Med Virol* 2020; **92**: 568-576 [PMID: 32134116 DOI: 10.1002/jmv.25748]

7 **Guan WJ**, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J* 2020; **55** [PMID: 32217650 DOI: 10.1183/13993003.00547-2020]

8 **Guo T**, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020; **5**: 811-818 [PMID: 32219356 DOI: 10.1001/jamacardio.2020.1017]

9 **Martins JT**, Li DJ, Baskin LB, Jialal I, Keffer JH. Comparison of cardiac troponin I and lactate dehydrogenase isoenzymes for the late diagnosis of myocardial injury. *Am J Clin Pathol* 1996; **106**: 705-708 [PMID: 8980345 DOI: 10.1093/ajcp/106.6.705]

10 **Jaffe AS**, Landt Y, Parvin CA, Abendschein DR, Geltman EM, Ladenson JH. Comparative sensitivity of cardiac troponin I and lactate dehydrogenase isoenzymes for diagnosing acute myocardial infarction. *Clin Chem* 1996; **42**: 1770-1776 [PMID: 8906075]

11 **Li B**, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clin Res Cardiol* 2020; **109**: 531-538 [PMID: 32161990 DOI: 10.1007/s00392-020-01626-9]

12 **Schiffrin EL**, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. *Am J Hypertens* 2020; **33**: 373-374 [PMID: 32251498 DOI: 10.1093/ajh/hpaa057]

13 **South AM**, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. *Am J Physiol Heart Circ Physiol* 2020; **318**: H1084-H1090 [PMID: 32228252 DOI: 10.1152/ajpheart.00217.2020]

14 **Zheng YY**, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol* 2020; **17**: 259-260 [PMID: 32139904 DOI: 10.1038/s41569-020-0360-5]

15 **Antwi-Amoabeng D**, Beutler BD, Moody AE, Kanji Z, Gullapalli N, Rowan CJ. Management of hypertension in COVID-19. *World J Cardiol* 2020; **12**: 228-230 [PMID: 32547717 DOI: 10.4330/wjc.v12.i5.228]

16 **Lopes RD**, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L, Feldman A, D'Andréa Saba Arruda G, de Albuquerque DC, Camiletti AS, de Sousa AS, de Paula TC, Giusti KGD, Domiciano RAM, Noya-Rabelo MM, Hamilton AM, Loures VA, Dionísio RM, Furquim TAB, De Luca FA, Dos Santos Sousa ÍB, Bandeira BS, Zukowski CN, de Oliveira RGG, Ribeiro NB, de Moraes JL, Petriz JLF, Pimentel AM, Miranda JS, de Jesus Abufaiad BE, Gibson CM, Granger CB, Alexander JH, de Souza OF; BRACE CORONA Investigators. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. *JAMA* 2021; **325**: 254-264 [PMID: 33464336 DOI: 10.1001/jama.2020.25864]

17 **Li XL**, Li T, Du QC, Yang L, He KL. Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19. *World J Clin Cases* 2021; **9**: 5462-5469 [PMID: 34307600 DOI: 10.12998/wjcc.v9.i20.5462]

18 **Kanne JP**. Chest CT Findings in 2019 Novel Coronavirus (2019-nCoV) Infections from Wuhan, China: Key Points for the Radiologist. *Radiology* 2020; **295**: 16-17 [PMID: 32017662 DOI: 10.1148/radiol.2020200241]

19 **Shi H**, Han X, Zheng C. Evolution of CT Manifestations in a Patient Recovered from 2019 Novel Coronavirus (2019-nCoV) Pneumonia in Wuhan, China. *Radiology* 2020; **295**: 20 [PMID: 32032497 DOI: 10.1148/radiol.2020200269]

**Footnotes**

**Institutional review board statement:** Approval was obtained from the Ethics Committee of Wenzhou Central Hospital (approval number: L2020-01-037).

**Informed consent statement:** Informed consent was waived by the Ethics Committee of Wenzhou Central Hospital due to the retrospective nature of this study.

**Conflict-of-interest statement:** The authors declare no conflict of interest for this article.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review**: Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 30, 2021

**First decision:** July 16, 2021

**Article in press:** November 25, 2021

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Kute VB, Sivanand N, Sun C **S-Editor:** Wang JJ **L-Editor:** Wang TQ **P-Editor:**

**Table 1 Characteristics of the patients (*n* = 140)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic** | **Mild illness (*n* = 114)** | **Severe illness (*n* = 26)** | ***P* value** |
| Age (yr, %) | 43.2 ± 14.0 | 54.7 ± 13.8 | 0.98 |
| Female (*n*, %) | 56 (49.1) | 9 (34.6) | 0.20 |
| Comorbidities (*n*) |  |  |  |
| Hypertension | 22 (19.3) | 10 (38.5) | 0.07 |
| Diabetes | 5 (4.4) | 1 (3.8) | 1.0 |
| Chronic obstructive pulmonary disease | 3 (2.6) | 0 | 1.0 |
| Chronic renal failure | 0 | 2 (7.7) | 1.0 |
| Coronary heart disease | 1 (0.9) | 2 (7.7) | 0.09 |
| Malignant tumor | 2 (1.8) | 2 (7.7) | 0.16 |
| Hepatitis B | 10 (8.8) | 3 (11.5) | 0.71 |
| Connective tissue disease | 1 (0.9) | 0 | 0.08 |
| Gout | 2 (1.8) | 1 (3.8) | 0.46 |
| Symptoms (*n*, %) |  |  |  |
| Fever | 86 (75.4) | 24 (92.3) | 0.06 |
| Cough | 61 (53.5) | 21 (80.8) | 0.01 |
| Expectoration | 34 (29.8) | 17 (65.4) | < 0.01 |
| Fatigue | 15 (13.2) | 5 (19.2) | 0.53 |
| Chest pain | 2 (1.8) | 2 (7.7) | 0.16 |
| Myalgia | 8 (7.0) | 2 (7.7) | 1.0 |
| Headache | 5 (4.4) | 1 (3.8) | 1.0 |
| Sore throat | 14 (12.3) | 2 (7.7) | 0.74 |
| Shortness of breath | 7 (6.1) | 8 (30.8) | < 0.01 |
| Diarrhea | 12 (10.5) | 2 (7.7) | 1.0 |

**Table 2 Laboratory test results of the patients (*n* = 140)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Mild illness (*n* = 114)** | **Severe illness (*n* = 26)** | ***P* value** |
| Leukocyte count (× 109/L) | 5.01 ± 1.85 | 4.67 ± 1.84 | 0.398 |
| Neutrophil count (× 109/L) | 3.15 ± 1.41 | 3.55 ± 1.88 | 0.308 |
| Lymphocyte count (× 109/L) | 1.4 ± 0.59 | 0.74 ± 0.31 | < 0.001 |
| Hemoglobin (g/L) | 136.13 ± 14.43 | 130.73 ± 15.18 | 0.09 |
| Platelet count (× 109/L) | 201.48 ± 72.45 | 164.35 ± 62.69 | 0.017 |
| Alanine aminotransferase (U/L) | 29.26 ± 29.67 | 35.69 ± 25.43 | 0.309 |
| Aspartate transaminase (U/L) | 27.97 ± 17.45 | 41.54 ± 26.22 | 0.017 |
| Total serum protein (g/L) | 70.27 ± 5.08 | 65.38 ± 5.19 | < 0.001 |
| Albumin (g/L) | 45.71 ± 33.39 | 37.42 ± 3.55 | 0.209 |
| Prealbumin (g/L) | 198.66 ± 50.55 | 123.13 ± 47.11 | < 0.001 |
| Blood urea nitrogen (mmol/L) | 3.71 ± 5.96 | 5.96 ± 10.91 | 0.303 |
| Blood creatinine (μmol/L) | 172.63 ± 34.15 | 159.24 ± 433.95 | 0.319 |
| Blood uric acid (μmol/L) | 241.84 ± 89.51 | 194.92 ± 96.27 | 0.019 |
| Creatine kinase (U/L) | 103.54 ± 180.73 | 211.49 ± 379.39 | 0.168 |
| Lactate dehydrogenase (U/L) | 202.94 ± 63.87 | 299.35 ± 68.82 | < 0.001 |
| C-reactive protein (mg/L) | 14.61 ± 19.35 | 52.48 ± 29.63 | < 0.001 |
| Erythrocyte sedimentation rate (mm/h) | 23.68 ± 14.36 | 33.25 ± 15.00 | 0.003 |
| Arterial partial pressure of oxygen (kPa) | 13.23 ± 4.00 | 11.06 ± 2.91 | 0.01 |
| Oxygenation index (mmHg) | 460.80 ± 138.71 | 324.62 ± 61.52 | < 0.001 |

**Table 3 Radiologic characteristics of the patients (*n* = 140)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Mild illness (*n* = 114)** | **Severe illness (*n* = 26)** | ***P* value** |
| Affected sites (*n*, %) |  |  |  |
| Left upper lobe | 90 (78.9) | 16 (61.5) | 0.08 |
| Left lower lobe | 107 (93.9) | 23 (88.5) | 0.39 |
| Right upper lobe | 86 (75.4) | 14 (53.8) | 0.052 |
| Right middle lobe | 73 (64.0) | 19 (73.1) | 0.49 |
| Right lower lobe | 105 (92.1) | 22 (84.6) | 0.26 |
| Bilateral lungs | 109 (95.6) | 26 (100.0) | 0.58 |
| Features (*n*, %) |  |  |  |
| Irregular patches | 110 (96.5) | 23 (88.5) | 0.12 |
| Ground-glass opacity | 90 (78.9) | 6 (23.1) | < 0.0001 |
| Consolidation | 29 (25.4) | 26 (100.0) | < 0.0001 |
| Nodules | 12 (10.5) | 0 | 0.12 |
| Wedge-shaped opacity | 1 (0.9) | 4 (15.4) | 0.004 |
| Pleural effusion | 3 (2.6) | 8 (30.8) | < 0.0001 |

徽标, 公司名称

描述已自动生成

Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com

QR 代码

描述已自动生成

**© 2022 Baishideng Publishing Group Inc. All rights reserved.**